Latest News on Trending Topics Across the World

Cleveland Clinic

As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings.
A new Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment.
In one of the largest real-world studies to date examining obesity treatment use and long-term weight changes after GLP-1 discontinuation, researchers at Cleveland Clinic found that many patients successfully stabilized their weight after one year through alternative treatments and therapeutic lifestyle interventions.
The findings published in the journal Diabetes, Obesity and Metabolism.

Research Results
MEDICINE